Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy

Part of paid clinical trials in Newport Beach, California.

Sponsor
Hoag Memorial Hospital Presbyterian
Study ID
NCT00004040
Phase
PHASE2
Status
Withdrawn

Conditions

  • Leukemia
  • Multiple Myeloma and Plasma Cell Neoplasm

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • recombinant interferon alfa — BIOLOGICAL
  • rituximab — BIOLOGICAL

Study Details

RATIONALE: Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Biological therapies such as interferon alfa-2b use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase II trial to study the effectiveness of rituximab or interferon alfa-2b in treating patients who have chronic lymphocytic leukemia or multiple myeloma in remission.

Key Dates

Start date
Jun 30, 1998
Status verified
Aug 2015
Primary completion
Jun 30, 1999
Completion
Jun 30, 1999

Study Design

Enrollment
0 participants (actual)
Primary purpose
TREATMENT

Locations (3)

FacilityCityStateZIPSite coordinators
Hoag Memorial Hospital PresbyterianNewport BeachCalifornia92658-
Baptist Regional Cancer Center - KnoxvilleKnoxvilleTennessee37901-
St. Joseph Regional Cancer CenterBryanTexas77802-

Find similar trials in Newport Beach, CA

By condition
Leukemia (other)
By specialty
OncologyBlood cancer
By research site
Hoag Memorial Hospital Presbyterian· Newport Beach, CABaptist Regional Cancer Center - Knoxville· Knoxville, TNSt. Joseph Regional Cancer Center· Bryan, TX

Related Studies